Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 trial of ABX-01

Next Previous
Trial Profile

A phase 1 trial of ABX-01

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABX 01 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 24 Feb 2026 According to a Centauri Therapeutics media release, the company has secured euro 6M from AMR Action Fund, extending the Company's Series A round to euro 30M. The investment will support the completion of Phase I clinical studies for CTX-187, Centauri's ead clinical candidate in the ABX-01 programme, and will expand the scope of additional research activities in preparation for Phase II.
  • 29 Jul 2025 According to a Centauri Therapeutics media release, company announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-Xs total support from 2019 to date to $12.3M.
  • 29 Jul 2025 According to a Centauri Therapeutics media release, company plans to progress a first in human clinical study in early 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top